ロード中...
Combined treatment with escitalopram and memantine increases gray matter volume and cortical thickness compared to escitalopram and placebo in a pilot study of geriatric depression.
BACKGROUND: Geriatric depression with subjective cognitive complaints increases the risk of Alzheimer’s Disease (AD). Memantine is a cognitive enhancer used to treat AD. In a 6-month double-blind randomized placebo-controlled trial of escitalopram and memantine (ESC/MEM), ESC/MEM improved cognition...
保存先:
| 出版年: | J Affect Disord |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7368564/ https://ncbi.nlm.nih.gov/pubmed/32663977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jad.2020.05.092 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|